FDAnews Drug Daily Bulletin

Oct. 4, 2012 | Vol. 9 No. 195

Nonhormonal Hot Flash Therapy Meets Phase III Goals

Noven Pharmaceuticals reported positive data from separate 12- and 24-week Phase III trials evaluating low-dose mesylate salt of paroxetine for reducing the frequency and severity of moderate-to-severe vasomotor symptoms associated with the menopause.
Genetic Engineering & Biotechnology News

Register Now
Print This Page
Email This Article
RSS
Archives

Full Issue FDA Advisers Recommend Merck Insomnia Drug; Downplay Need for Additional Trials Senate Preps Track-and-Trace, Compounding Reform Bills for Floor Vote Ranbaxy Compliance Reforms Reflect FDA Manufacturing Recommendations

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.